The Week

Cytokinetics (CYTK) fell 6.76% this week to $68.78, while the S&P 500 slipped just 0.08%, leaving the stock roughly 6.68 percentage points behind the benchmark. The week was choppy rather than one-directional: Monday (Sep 14) opened at $73.505 and hit an intraday high of $74.65, but Tuesday (Sep 15) opened lower and the stock never recovered. Friday (Sep 18) closed near the low end of the $68.15-$70.18 range. Weekly amplitude was 8.84%, and average daily volume of about 2.52m shares ran 44.81% above the median. No major catalyst emerged this week, with only routine corporate announcements.

Analyst Ratings

As of this week, 22 institutions cover the stock: 13 buy, 7 over, 2 hold, and none under or sell. The consensus rating is buy, with a consensus target of $109.90, implying about 59.78% upside from the latest price. Targets range from $85 to $146, showing a wide spread. Within the biotech industry, CYTK ranks 19th out of 501 names on the ratings leaderboard.

The Week Ahead

Macro data dominates the calendar from Tuesday to Thursday: the Richmond Fed composite index on Tuesday (Sep 22), EIA weekly crude and Cushing inventories on Wednesday (Sep 23), and jobless claims, current account balance and new home sales on Thursday (Sep 24). No company-specific earnings or event dates are lined up, so attention is likely to track biotech sector sentiment and macro liquidity shifts.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.